Receptor-guided engineering of oncolytic vaccinia creates a synthetic support niche for off-the-shelf NK cell therapy

Oncolytic vaccinia virus (VV) is a compatible viral chassis for off-the-shelf expanded, frozen, and thawed natural killer (NK) cells, supporting function at effector-to-target ratios as low as 1:10.

• Why it matters: Adoptive NK therapy and oncolytic viruses are often engineered separately, even though manufacturing can alter NK chemokine responsiveness, cytokine dependence, and sustained function in solid tumors.
• What they did: The team mapped manufacturing-associated NK phenotypes under antiviral pressure, compared VV with HSV-1, then used receptor-guided sequential screening to select a five-factor program (CXCL11, IL-15, IL-27, IL-2, IL-1{beta}) and tested consolidation in vivo.
• The result: Consolidating these signals increased antitumor activity but linked constitutive IL-1{beta} to systemic inflammation, so chemically inducible IL-2/IL-1{beta} control retained in vivo antitumor activity while limiting systemic toxicity.

AI summary of the abstract · may contain errors · not medical advice · read the paper.